Support our Foundation of Myology project
Long-term stabilisation or improvement in motor function in adults with severe SMA treated with risdiplam
Partager sur
An observational study tracked changes in motor scores in 72 patients, aged between 23 and 42, with type Ic or II proximal spinal muscular atrophy (SMA), who had severe motor deficits and were being treated with risdiplam (Evrysdi®).
- After a median treatment duration of three years, the RULM (Revised Upper Limb Module) and ATEND (Adapted Test of Neuromuscular Disorders) scores improved or stabilised in 43 per cent and 60 per cent of patients, respectively.
- Nearly 90 per cent of patients reported that their general well-being had stabilised or improved.
- The ATEND scale complements the RULM scale in assessing changes in motor function in patients with severe SMA.
This study suggests that treatment with risdiplam may be beneficial for adults with severe motor limitations due to long-standing disease.
